Construction of minicircle DNA vectors capable of correcting familial hypercholesterolemia phenotype in a LDLR-deficient mouse model

Gene Therapy

Volumn 23, Issue 8-9, 2016, Pages 657-663

  Hou, X ^a   Jiao, R ^a,b   Guo, X ^a,c   Wang, T ^a   Chen, P ^a   Wang, D ^a   Chen, Y ^a   He, C Y ^a   Chen, Z Y ^a  

^a SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^b JINAN UNIVERSITY   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MC5 DNA; MC7 DNA; MINICIRCLE DNA; STEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DNA STRUCTURE; DNA VECTOR; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEPATIC CONTROL REGION; HUMAN; HUMAN CELL; IN VITRO STUDY; KOZAK SEQUENCE; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROMOTER REGION; RNA TRANSLATION; START CODON; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DNA RESPONSIVE ELEMENT; GENE THERAPY; GENE VECTOR; GENETICS; HEP-G2 CELL LINE; HYPERCHOLESTEROLEMIA; LIVER; METABOLISM; PHENOTYPE; PROCEDURES;

ANIMALS; APOLIPOPROTEINS E; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HEP G2 CELLS; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; MICE; MICE, INBRED C57BL; PHENOTYPE; RECEPTORS, LDL; RESPONSE ELEMENTS;

EID: 84966667365     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2016.37     Document Type: Article

References (33)

1. Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc Natl Acad Sci USA 1974; 71: 788-792.
2. Van Craeyveld E, Jacobs F, Gordts SC, De Geest B. Gene therapy for familial hypercholesterolemia. Curr Pharm Des 2011; 17: 2575-2591.
3. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214-225.
4. Apstein CS, Zilversmit DB, Lees RS, George PK. Effect of intessive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis 1978; 31: 105-115.
5. Leonard JV, Clarke M, Macartney FJ, Slack J. Progression of atheroma in homozygous familial hypercholesterolaemia during regular plasma exchange. Lancet 1981; 2: 811.
6. Kassim SH, Li H, Bell P, Somanathan S, Lagor W, Jacobs F et al. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther 2013; 24: 19-26.
7. Ose L. An update on familial hypercholesterolaemia. Ann Med 1999; 31(Suppl 1): 13-18.
8. Smith JR, Osborne TF, Goldstein JL, Brown MSIdentification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J Biol Chem 1990; 265: 2306-2310.
9. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46.
10. Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 2004; 6: 663-672.
11. Hibbitt OC, McNeil E, Lufino MM, Seymour L, Channon K, Wade-Martins R. Longterm physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs. Mol Ther 2010; 18: 317-326.
12. Hibbitt OC, Harbottle RP, Waddington SN, Bursill CA, Coutelle C, Channon KM et al. Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. J Gene Med 2007; 9: 488-497.
13. Chen ZY, Riu E, He CY, Xu H, Kay MA. Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther 2008; 16: 548-556.
14. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8: 495-500.
15. Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat Biotechnol 2010; 28: 1287-1289.
16. Dietz WM, Skinner NEB, Hamilton SE, Jund MD, Heitfeld SM, Litterman AJ et al. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8(+) T-cell responses. Mol Ther 2013; 21: 1526-1535.
17. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010; 7: 197-199.
18. Stenler S, Blomberg P, Smith CE. Safety and efficacy of DNA vaccines: plasmids vs minicircles. Hum Vaccin Immunother 2014; 10: 1306-1308.
19. Sudhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science 1985; 228: 815-822.
20. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
21. Jacobs F, Van Craeyveld E, Feng Y, Snoeys J, De Geest B. Adenoviral low density lipoprotein receptor attenuates progression of atherosclerosis and decreases tissue cholesterol levels in a murine model of familial hypercholesterolemia. Atherosclerosis 2008; 201: 289-297.
22. WHO. The WHO Expert Committee on Biological Standardization 56th report: Number 941. World Health Organization: Geneva, 2007.
23. FDA. Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications. November 2007.
24. EMEA. Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products: EMEA/273974/2005. London, 17 November 2005.
25. Stenler S, Wiklander OP, Badal-Tejedor M, Turunen J, Nordin JZ, Hallengard D et al. Micro-minicircle gene therapy: implications of size on fermentation, complexation, shearing resistance, and expression. Mol Ther Nucleic Acids 2014; 2: e140.
26. Catanese Jr DJ, Fogg JM, Schrock 2nd DE, Gilbert BE, Zechiedrich L. Supercoiled minivector DNA resists shear forces associated with gene therapy delivery. Gene Therapy 2012; 19: 94-100.
27. Hill AB, Chen M, Chen CK, Pfeifer BA, Jones CH. Overcoming gene-delivery hurdles: physiological considerations for nonviral vectors. Trends Biotechnol 2015; 34: 91-105.
28. Zhang Y, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther 2012; 20: 1298-1304.
29. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-466.
30. Sudhof TC, Van der Westhuyzen DR, Goldstein JL, Brown MS, Russell DW. Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene. J Biol Chem 1987; 262: 10773-10779.
31. Dang Q, Walker D, Taylor S, Allan C, Chin P, Fan J et al. Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus. J Biol Chem 1995; 270: 22577-22585.
32. Long GL, Chandra T, Woo SL, Davie EW, Kurachi K. Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant. Biochemistry 1984; 23: 4828-4837.
33. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene 2002; 299: 1-34.